Clinical Trial: Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07133659) titled 'Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study' on Aug. 14.

Brief Summary: This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and continued for up to 24 weeks. The study aims to acquire experience on use of avatrombopag and explore the efficacy and safety of lower starting dose of avatrombopag

Study Start Date: June 08

Study Type: INTERVENTIONAL

Condition: ITP - Immune Thrombocytopenia

In...